Compare stats with Graham. They are both projected to earn about $1.30 per share next year. GHM however has a superior balance sheet with $6/share in cash and no debt. GHM is really compelling. Is it a takeover prospect with its puny market cap?
Sentiment: Strong Buy
Right- no competition for a treatment for this debilitating condition. This was the first trial ever to treat Menieres. I listened to yesterdays conference call, the data is positive.